Drugs & Targets FDA approves Tafinlar + Mekinist for pediatric patients with low-grade glioma with a BRAF V600E mutation March 17, 2023Vol.49 No.11
Drugs & Targets Prelude Therapeutics to collaborate with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic cancers March 17, 2023Vol.49 No.11
Drugs & Targets FDA broadens indication for Verzenio in HR+, HER2-, node-positive, high-risk early breast cancer March 10, 2023Vol.49 No.10
Drugs & Targets FDA approves label expansion for VENTANA PD-L1 assay to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo March 10, 2023Vol.49 No.10
Drugs & Targets FDA updates mammography regulations to require reporting of breast density information and enhance facility oversight March 10, 2023Vol.49 No.10
Drugs & Targets Point32Health, Foundation Medicine expand access to comprehensive genomic profiling for advanced cancer March 03, 2023Vol.49 No.09
Drugs & Targets C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan March 03, 2023Vol.49 No.09
Drugs & Targets HRA Pharma & Celnova Pharma partner to launch medicines in South America for adrenocortical carcinoma March 03, 2023Vol.49 No.09
Drugs & Targets Gritstone bio and NCI collaborate to evaluate neoantigen cell therapy + vaccine for mutant KRAS solid tumors February 17, 2023Vol.49 No.07
